Trials / Completed
CompletedNCT04709835
Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19
A Phase II Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Antiviral Activity, Safety, Pharmacokinetics, and Efficacy of RO7496998 (AT-527) in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 104 (actual)
- Sponsor
- Hoffmann-La Roche · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This randomized study evaluates the antiviral activity, safety, efficacy and pharmacokinetics of AT-527 versus a placebo in participants with mild or moderate coronavirus disease (COVID-19) who are not hospitalized.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AT-527 | Results from Arm AT-527 500 mg determined the dose and regimen to be used for AT-527 1100 mg. |
| DRUG | Placebo | The dose and regimen of the placebo will match that of the respective AT-527 comparator arm. |
Timeline
- Start date
- 2021-02-03
- Primary completion
- 2021-09-17
- Completion
- 2021-10-13
- First posted
- 2021-01-14
- Last updated
- 2022-10-26
- Results posted
- 2022-10-13
Locations
12 sites across 6 countries: Canada, Greece, Ireland, Latvia, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04709835. Inclusion in this directory is not an endorsement.